5655-01-6

Basic information

• Product Name: 1,5-DIHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONE
• Synonyms: 1,5-DIHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONE;4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro- (8CI,9CI);4H-Pyrrolo3,2-dpyrimidin-4-one, 1,5-dihydro-;1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one(3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one);1,4,6-Triazainden-7(6H)-one;1H-pyrrolo[3,2-d]pyriMidin-4(5H)-one;1H,4H,5H-pyrrolo[3,2-d]pyriMidin-4-one;4H-Pyrrolo[3,2-d]pyriMidin-4-one, 3,5-dihydro-
• CAS NO: 5655-01-6
• Molecular Formula: C₆H₅N₃O
• Molecular Weight: 135.1234
• EINECS: 1533716-785-6
• Product Categories: PYRIMIDINE;Heterocycle-Pyrimidine series
• Mol File: 5655-01-6.mol

Chemical Properties

• Melting Point: >300℃
• Boiling Point: 392.9 °C at 760 mmHg
• Flash Point: 191.4 °C
• Appearance: /
• Density: 1.62
• Vapor Pressure: 2.22E-06mmHg at 25°C
• Refractive Index: 1.784
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.02±0.20(Predicted)
• CAS DataBase Reference: 1,5-DIHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-DIHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONE(5655-01-6)
• EPA Substance Registry System: 1,5-DIHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONE(5655-01-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5655-01-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1,5-Dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one is used as a building block for the synthesis of various complex organic molecules. Its unique structure allows for the formation of diverse chemical entities, making it a valuable intermediate in the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Biochemical Research:
In the field of biochemistry, 1,5-Dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one is used as a research tool to study the interactions of molecules with biological systems. Its heterocyclic nature enables it to form stable complexes with enzymes, receptors, and other biomolecules, providing insights into their structure and function.
Used in Pharmaceutical Development:
1,5-Dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one is used as a potential therapeutic agent in the development of new drugs. Its chemical properties and ability to interact with biological targets make it a promising candidate for the treatment of various diseases, including cancer, neurological disorders, and infectious diseases.
Used in Material Science:
In material science, 1,5-Dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one is used in the development of novel materials with unique properties. Its incorporation into polymers, coatings, and other materials can lead to improved performance, such as enhanced stability, increased biocompatibility, or tailored electronic properties.
Used in Environmental Applications:
1,5-Dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one is used in environmental remediation processes, such as the degradation of pollutants or the removal of heavy metals from water. Its chemical reactivity and ability to form complexes with contaminants make it a potential candidate for the development of new environmental technologies.

InChI:InChI=1/C6H5N3O/c10-6-5-4(1-2-7-5)8-3-9-6/h1-3,7H,(H,8,9,10)

Upstream product

• 84905-79-3 4-Oxo-3,4-dihydropyrrolo<3.2-d>pyrimidine-7-carboxylic acid 
• 144216-57-9 4-methoxy-5H-pyrrolo<3,2-d>pyrimidine 
• 118721-29-2 2,7-Dibromo-4-oxo-3,4-dihydropyrrolo<3,2-d>pyrimidine 
• 3473-63-0 formamidine acetic acid 
• 252932-48-2 3-amino-2-ethoxycarbonylpyrrole 
• 474555-68-5 8-oxo-7H-2-phenylpyrimido[5,4-c]pyridazin-6-thione 
• 14985-77-4 4-hydroxy-5-phenylazo-6-methylpyrimid-2-thione 
• 144216-56-8 6-(2,2-dimethoxyethyl)-4-methoxypyrimidine-5-amine 
• 144216-55-7 6-(2,2-dimethoxyethyl)-4-methoxy-5-nitropyrimidine 
• 779326-74-8 4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carboxylic acid methyl ester 
• 252932-49-3 3-amino-2-ethoxycarbonylpyrrole hydrochloride 
• 290-87-9 1,3,5-Triazine 
• 898803-80-0 2-amino-3-pyrrolecarboxylate methyl ester 
• 108290-86-4 2-amino-1H-pyrrole-3-carboxylic acid ethyl ester 

Downstream Products

• 84905-80-6 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine 
• 1010701-18-4 7-((methyl((2-phenyl-1,3-dioxan-4-yl)methyl)amino)-methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one 
• 1026012-16-7 5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 299916-62-4 7-N-benzyloxymethyl-9-bromo-9-deaza-6-O-methylhypoxanthine 
• 299916-67-9 (1S)-1-(7-N-benzyloxymethyl-9-deaza-6-O-methylhypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 
• 364046-18-4 1S-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1-C-[(4-methyoxypyrrolo[3,2-d]pyrimidin-9-N-(benzyloxomethyl)-7-yl)]-1,4-imino-2,3-O-isopropylidine-D-ribitol 
• 364046-19-5 1S-N-tert-butoxycarbonyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1-C-[(4-methyoxypyrrolo[3,2-d]pyrimidin-9-N-(benzyloxomethyl)-7-yl)]-1,4-imino-2,3-O-isopropylidine-D-ribitol 
• 916213-53-1 C₆H₄BrN₃ 
• 93587-26-9 7-nitro-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one 
• 93587-23-6 7-bromo-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one 
• 1010701-29-7 C₂₁H₂₆N₄O₃ 
• 1193682-68-6 3-(benzyl((4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)amino)propanol 
• 1334712-78-5 5-(4-chlorophenyl)-7-(oxan-4-yl)-5H-pyrrolo[3,2-d]pyrimidine 
• 1384950-68-8 tert-butyl 4-(5-methyl-7-(4-methanesulfonylphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)piperidin-1-carboxylate 

Relevant articles and documents

Novel Substituted Purine Isosteres: Synthesis, Structure-Activity Relationships and Cytotoxic Activity Evaluation

A number of pyrrolo[2,3-c]pyridines, pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines were designed and synthesized as antiproliferative agents. The target compounds possessed selected substituents in analogous positions on the central scaffold th

Synthesis method of 4-chloropyrrolopyrimidine

The invention belongs to the technical field of chemical synthesis, and discloses a synthesis method of 4-chloropyrrolopyrimidine, which comprises the following steps: adding an acid solution into anorganic mixed solution of a compound of a formula III, a

COMPOSITIONS AND METHODS FOR THERAPY OF PROSTATE CANCER USING DRUG COMBINATIONS TO TARGET POLYAMINE BIOSYNTHESIS AND RELATED PATHWAYS

Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue. The methods are for use in individuals who have been diagnosed with, or are suspected of having or at risk for developing androgen sensitive prostate cancer (AS-CaP), or Castration recurrent CaP (CR-CaP), or benign prostate hyperplasia (BPH). The disclosure includes use of inhibitors of methylthioadenosine phosphorylase (MTAP), and a polyamine analog that upregulates polyamine catabolism by increasing spermidine/spermine Nl -acetyl transferase (SAT1) activity, such as methylthio-DADMe-Immucillin (MTDIA), andl),N(11)-bisethylnorspermine (BENSpm), respectively. Pharmaceutical formulations that contain a combination of the inhibitor of the methionine salvage pathway and a polyamine analogue are included, as are kits that contain such agents.

ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES

Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE

Provided are compounds of Formula (I) as described herein. Compounds of Formula (I) are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula (I), as well as methods of treating viral infections using compounds of Formula (I).

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

New Enzyme Inhibitor Compounds

Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.